158103-31-2

Downstream Products

• 221301-28-6 3-(5-amino-2-methoxy-benzyl)-6-(7-chloro-quinolin-2-ylmethoxy)-2,2-dimethyl-chroman-4-one 
• 158103-32-3 3-(5-Amino-2-methoxybenzyl)-6-(5,6-difluorobenzothiazol-2-ylmethoxy)-2,2-dimethylchroman-4-one 
• 221301-30-0 N-{3-[6-(7-chloro-quinolin-2-ylmethoxy)-2,2-dimethyl-4-oxo-chroman-3-ylmethyl]-4-methoxy-phenyl}-C,C,C-trifluoro-methanesulfonamide 

Relevant academic research and scientific papers

Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists

A new series of cysLT1 receptor antagonists represented by CP-288,886 (7) and CP-265,298 (8) were developed which are equipotent to clinical cysLT1 receptor antagonists Zafirlukast (1) and Pranlukast (2).

SULFONAMIDE DERIVATIVES OF BENZENEFUSED HYDROXY SUBSTITUTED CYCLOALKYL AND HETEROCYCLIC RING COMPOUNDS

Compounds of the formula STR1 and pharmaceutically acceptable salts and prodrugs thereof, wherein X 1, Ar, X, Y 1, R. sup.1, R. sup.2, R 3, R 5 and n are defined below, which are inhibitors of the production of leukotrienes and/or blockers of leukotriene